Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 27;9(3):629.
doi: 10.3390/jcm9030629.

Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple

Mariadelina Simeoni  1 , Alessandra F Perna  1 , Giorgio Fuiano  2
Affiliations
Review

Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple

Mariadelina Simeoni et al. J Clin Med. .

Abstract

: Secondary hyperparathyroidism (SHPTH) is a major complication in patients on maintenance hemodialysis burdened with high cardiovascular risk. Hypertension is also a high prevalence complication contributing to an increase in the mortality rate in hemodialysis patients. A possible association between SHPTH and hypertension has been widely reported in the literature and several pathogenetic mechanisms have been described. There is evidence that the decrease of plasma iPTH levels are correlated with hypertension correction in hemodialysis patients undergoing parathyroidectomy and oral calcimimetics administration. We have observed a similar behaviour also in a patient on chronic hemodialysis treated with Etelcalcetide. Even if this is an isolated observation, it could stimulate future investigation, possibly in dedicated clinical trials.

Keywords: calcimimetic; hemodialysis; hypertension; secondary hyperparathyroidism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathogenesis flow-chart of SHPTH development in CKD.
Figure 2
Figure 2
Mechanisms involved in hyperparathyroidism-related blood pressure increase. VSMC: vascular smooth muscle cell.
Figure 3
Figure 3
Unrelated blood pressure response to dry weight reduction in our patient before starting Etelcalcetide. OH: overhydration at body composition monitoring (BCM).
Figure 4
Figure 4
Variations of blood pressure, heart rate, albumin corrected-serum calcium in response to iPTH reduction induced by ETEL (Etelcalcetide).
See this image and copyright information in PMC

References

    1. Rottembourg J., Urena-Torres P., Toledano D., Gueutin V., Hamani A., Coldefy O., Hebibi H., Guincestre T., Emery C. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clin. Kidney J. 2019;12:871–879. doi: 10.1093/ckj/sfz021. - DOI - PMC - PubMed
    1. van der Plas W.Y., Noltes M.E., van Ginhoven T.M., Kruijff S. Secondary and Tertiary Hyperparathyroidism: A Narrative Review. Scand J. Surg. 2019 doi: 10.1177/1457496919866015. - DOI - PubMed
    1. D’Onofrio G., Simeoni M., Rizza P., Caroleo M., Capria M., Mazzitello G., Sacco T., Mazzuca E., Panzino M.T., Cerantonio A., et al. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Ren. Fail. 2017;39:45–53. doi: 10.1080/0886022X.2016.1244077. - DOI - PMC - PubMed
    1. Coppolino G., Lucisano G., Rivoli L., Simeoni M., De Paola L., Timpano R., Palmieri C., Fuiano G. Serum β-Crosslaps as Predictor of Long-term Parathyroid Hormone Levels in Hemodialysis Patients. J. Investig. Med. 2015;63:539–544. doi: 10.1097/JIM.0000000000000140. - DOI - PubMed
    1. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., Andress D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31–38. doi: 10.1038/sj.ki.5002009. - DOI - PubMed

LinkOut - more resources